Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday.
That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone.
The price of the new shares would depend on the firm’s average share price over the five days before the secondary offering, Chang said. Companies usually offer discounts of up to 30 percent, she said.
As Senhwa Biosciences shares have stayed above NT$100 in the past few months, the company expects to raise at least NT$1.5 billion from the issuance of 15 million new shares, Chang said.
The fresh funds would fuel the company’s research and development of Silmitasertib, or CX-4945, which is a small-molecule drug for cancers, such as bile duct cancer, but has shown potential to combat the novel coronavirus with its capability to curb replication of the ribonucleic acid virus.
The company plans to test the drug on mice to evaluate its efficacy in cooperation with the US National Institutes of Health (NIH) next month, Senhwa Biosciences chief executive officer Soong Tai-sen (宋台生) said by telephone yesterday.
The preparation of the animal tests would take some time, as the mice first need to be genetically engineered to have a human version of a protein known as the angiotensin-converting enzyme 2 receptor, which the coronavirus uses as its point of entry, Soong said.
He expects the animal tests to be completed by the end of next month.
As conducting human tests with the experimental drug would be expensive, with an average cost of US$80,000 per subject, Senhwa Biosciences plans to apply to foreign agencies, such as the US Biomedical Advanced Research and Development Authority, for sponsorship, Soong said.
“Although the development of vaccines against COVID-19 is eye-catching, I think drugs will be the real solution for the pandemic, as COVID-19 antibodies might fade in less than two months, according to recent studies,” Soong said.
Senhwa Biosciences shares advanced 9.96 percent to NT$139.5 in Taipei trading yesterday, after an international team led by researchers at the University of California, San Francisco, identified Silmitasertib as one of the several drugs that could disrupt the viral takeover of cells.
The company’s shares have risen 120 percent from NT$63.5 in March, when the company began focusing on exploiting the experimental drug to treat COVID-19.
The demise of the coal industry left the US’ Appalachian region in tatters, with lost jobs, spoiled water and countless kilometers of abandoned underground mines. Now entrepreneurs are eyeing the rural region with ambitious visions to rebuild its economy by converting old mines into solar power systems and data centers that could help fuel the increasing power demands of the artificial intelligence (AI) boom. One such project is underway by a non-profit team calling itself Energy DELTA (Discovery, Education, Learning and Technology Accelerator) Lab, which is looking to develop energy sources on about 26,305 hectares of old coal land in
Taiwan’s exports soared 56 percent year-on-year to an all-time high of US$64.05 billion last month, propelled by surging global demand for artificial intelligence (AI), high-performance computing and cloud service infrastructure, the Ministry of Finance said yesterday. Department of Statistics Director-General Beatrice Tsai (蔡美娜) called the figure an unexpected upside surprise, citing a wave of technology orders from overseas customers alongside the usual year-end shopping season for technology products. Growth is likely to remain strong this month, she said, projecting a 40 percent to 45 percent expansion on an annual basis. The outperformance could prompt the Directorate-General of Budget, Accounting and
Netflix on Friday faced fierce criticism over its blockbuster deal to acquire Warner Bros Discovery. The streaming giant is already viewed as a pariah in some Hollywood circles, largely due to its reluctance to release content in theaters and its disruption of traditional industry practices. As Netflix emerged as the likely winning bidder for Warner Bros — the studio behind Casablanca, the Harry Potter movies and Friends — Hollywood’s elite launched an aggressive campaign against the acquisition. Titanic director James Cameron called the buyout a “disaster,” while a group of prominent producers are lobbying US Congress to oppose the deal,
Two Chinese chipmakers are attracting strong retail investor demand, buoyed by industry peer Moore Threads Technology Co’s (摩爾線程) stellar debut. The retail portion of MetaX Integrated Circuits (Shanghai) Co’s (上海沐曦) upcoming initial public offering (IPO) was 2,986 times oversubscribed on Friday, according to a filing. Meanwhile, Beijing Onmicro Electronics Co (北京昂瑞微), which makes radio frequency chips, was 2,899 times oversubscribed on Friday, its filing showed. The bids coincided with Moore Threads’ trading debut, which surged 425 percent on Friday after raising 8 billion yuan (US$1.13 billion) on bets that the company could emerge as a viable local competitor to Nvidia
RSS